×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XGN – exagen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/14
01:32 am
xgn
Exagen (XGN) was downgraded by Wall Street Zen from "hold" to "sell".
Low
Report
Exagen (XGN) was downgraded by Wall Street Zen from "hold" to "sell".
3/11
01:40 pm
xgn
Exagen (XGN) had its price target lowered by Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Exagen (XGN) had its price target lowered by Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.
3/11
11:30 am
xgn
Exagen (XGN) had its price target lowered by Craig Hallum from $12.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Exagen (XGN) had its price target lowered by Craig Hallum from $12.00 to $10.00. They now have a "buy" rating on the stock.
3/11
09:44 am
xgn
Exagen (XGN) had its price target lowered by KeyCorp from $15.00 to $10.00. They now have an "overweight" rating on the stock.
Low
Report
Exagen (XGN) had its price target lowered by KeyCorp from $15.00 to $10.00. They now have an "overweight" rating on the stock.
3/11
05:02 am
xgn
Avolta AG GAAP EPS of CHF 1.36, revenue of CHF 13.76B [Seeking Alpha]
Medium
Report
Avolta AG GAAP EPS of CHF 1.36, revenue of CHF 13.76B [Seeking Alpha]
3/11
04:29 am
xgn
Earnings Snapshot: Groupon Q4 North America local revenue +4%, billings +9% [Seeking Alpha]
Medium
Report
Earnings Snapshot: Groupon Q4 North America local revenue +4%, billings +9% [Seeking Alpha]
3/10
06:56 pm
xgn
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/10
06:52 pm
xgn
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence [Seeking Alpha]
Medium
Report
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/16
09:16 pm
xgn
Form 3 EXAGEN INC. For: Mar 16 Filed by: McKhann Chas
Low
Report
Form 3 EXAGEN INC. For: Mar 16 Filed by: McKhann Chas
3/16
07:17 pm
xgn
Form 4 EXAGEN INC. For: Mar 12 Filed by: ABALLI JOHN
Low
Report
Form 4 EXAGEN INC. For: Mar 12 Filed by: ABALLI JOHN
3/16
07:17 pm
xgn
Form 4 EXAGEN INC. For: Mar 12 Filed by: Black Jeffrey G.
Low
Report
Form 4 EXAGEN INC. For: Mar 12 Filed by: Black Jeffrey G.
3/10
09:23 am
xgn
Form 10-K EXAGEN INC. For: Dec 31
Low
Report
Form 10-K EXAGEN INC. For: Dec 31
3/10
08:04 am
xgn
Form 8-K EXAGEN INC. For: Mar 10
Medium
Report
Form 8-K EXAGEN INC. For: Mar 10
3/4
03:00 pm
xgn
Form 4 EXAGEN INC. For: Mar 03 Filed by: ABALLI JOHN
Low
Report
Form 4 EXAGEN INC. For: Mar 03 Filed by: ABALLI JOHN
2/25
07:12 pm
xgn
Form 4 EXAGEN INC. For: Feb 24 Filed by: ABALLI JOHN
Neutral
Report
Form 4 EXAGEN INC. For: Feb 24 Filed by: ABALLI JOHN
2/25
07:11 pm
xgn
Form 4 EXAGEN INC. For: Feb 24 Filed by: Black Jeffrey G.
Neutral
Report
Form 4 EXAGEN INC. For: Feb 24 Filed by: Black Jeffrey G.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Form 10-K EXAGEN INC. For: Dec 31
37.4%
12/20 Do Hedge Funds Love Exagen Inc. (XGN)? [Yahoo! Finance News] 23.8%
1/27 Form SC 13G EXAGEN INC. Filed by: RTW INVESTMENTS, LP 13.5%
9/18 Form S-1MEF EXAGEN INC. 10.6%
3/27 Form 4 EXAGEN INC. For: Mar 11 Filed by: PALLARES EBETUEL 10.0%
4/18 Exagen Inc. (NYSE: XGN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 6.5%
12/16 Is Affimed NV (AFMD) Going to Burn These Hedge Funds? [Yahoo! Finance News] 4.7%
10/21 Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America 3.9%
9/20 Form 424B4 EXAGEN INC. 2.6%
11/22 Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management 2.4%
12/20 Do Hedge Funds Love Exagen Inc. (XGN)? [Yahoo! Finance News] 23.8%
1/27 Form SC 13G EXAGEN INC. Filed by: RTW INVESTMENTS, LP 13.5%
9/18 Form S-1MEF EXAGEN INC. 10.6%
3/27 Form 4 EXAGEN INC. For: Mar 11 Filed by: PALLARES EBETUEL 10.0%
4/18 Exagen Inc. (NYSE: XGN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 6.5%
12/16 Is Affimed NV (AFMD) Going to Burn These Hedge Funds? [Yahoo! Finance News] 4.7%
10/21 Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America 3.9%
9/20 Form 424B4 EXAGEN INC. 2.6%
11/22 Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management 2.4%
TOP News Decliners
2/18
Exagen to Present at Cowen and Company 40th Annual Healthcare Conference
-28.0%
3/16 Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease -27.7%
3/26 Form 3 EXAGEN INC. For: Mar 24 Filed by: Zack Debra -24.8%
3/11 Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020 -13.3%
3/24 Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer -9.3%
2/7 Form SC 13G EXAGEN INC. Filed by: Hunt Holdings Limited Partnership -8.2%
11/21 Exagen Inc. Announces $26.2 Million Debt Refinancing -6.8%
4/29 Form DEF 14A EXAGEN INC. For: Apr 29 -6.6%
3/3 Exagen Inc. (NYSE: XGN) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. -6.3%
12/20 Exagen Inc. (NYSE: XGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
3/16 Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease -27.7%
3/26 Form 3 EXAGEN INC. For: Mar 24 Filed by: Zack Debra -24.8%
3/11 Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020 -13.3%
3/24 Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer -9.3%
2/7 Form SC 13G EXAGEN INC. Filed by: Hunt Holdings Limited Partnership -8.2%
11/21 Exagen Inc. Announces $26.2 Million Debt Refinancing -6.8%
4/29 Form DEF 14A EXAGEN INC. For: Apr 29 -6.6%
3/3 Exagen Inc. (NYSE: XGN) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. -6.3%
12/20 Exagen Inc. (NYSE: XGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: